Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders

CORAL SPRINGS, Florida, June 30, 2015 /PRNewswire/ --

Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions.  Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions.  Biotech companies in the news are:  Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS),  ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD),  Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent No. 9,066,903 entitled, "Pharmacological Treatment of Parkinson's Disease." The patent covers methods for the administration of eltoprazine, in combination with the anti-Parkinson's drug, levodopa (L-DOPA), for the treatment of Parkinson's disease.

"We are very pleased with the issuance by the USPTO of the patent covering the use of eltoprazine in treating patients with Parkinson's disease receiving L-DOPA and who suffer from L-DOPA induced dyskinesia. This new issuance helps the Company continue to build our intellectual property estate for eltoprazine," said Gerald E. Commissiong, President & CEO of Amarantus. "The Phase 2b clinical study has commenced with patient screening progressing well and now rapidly heading into the first randomization. We expect the first patient to be randomized in the trial very shortly. Initiation of patient screening is an important step forward in terms of ramping up the trial initiation process. We believe eltoprazine has tremendous potential to address a significant unmet therapeutic need or individuals with Parkinson's disease."

Read the full AMBS Press Releases at http://www.financialnewsmedia.com/profiles/ambs.html

Eltoprazine is a small molecule 5HT1A/1B partial agonist and the Amarantus is currently preparing to commence Phase 2b clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). PD-LID is an abnormal involuntary, movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson's disease. PD-LID occurs in approximately 60-80% of Parkinson's disease patients and is one of the most difficult problems facing people with the disease. This dyskinesia can be severely disabling and impact quality of life by prohibiting the ability to perform routine daily functions. 

In other biotech and pharmaceutical company news and developments:  Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) announced earlier this month additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a movement disorder associated with the treatment of Parkinson's disease. Patient diary data were analyzed to characterize the time course of troublesome LID and other Parkinson's disease states during waking hours, synchronized to the patients' wake-up times as well as to elucidate the impact of treatment with ADS-5102. These data showed that troublesome LID was reported throughout the day. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. In contrast, placebo-treated patients reported little change in their dyskinesia. These results (Abstract # 329) are being presented at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, California.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson's Disease and Movement Disorders held in San Diego.  "Data from the integrated analysis of Phase III studies continue to support the potential for NUPLAZID to safely and effectively treat Parkinson's disease psychosis, a condition for which there is no approved therapy in the United States," said Roger Mills, M.D., Executive Vice President, Development and Chief Medical Officer. "Furthermore, data from our open-label safety extension studies indicate that long-term administration of NUPLAZID is generally safe and well tolerated in patients with Parkinson's disease psychosis and that duration of antipsychotic effect may be maintained for longer than the six weeks investigated in our Phase III placebo-controlled efficacy studies."

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette's Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is seeking to apply its expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving patients' lives. The company's scientific excellence, integrated capabilities and experienced team position it to successfully achieve its goal of advancing new products along the entire continuum from the bench to the patient.  ACHN closed down slightly yesterday at $8.55 on over 2.5Million shares traded by the market close on Monday.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Amarantus BioScience Holdings, Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group, LLC